ANCA Vasculitis Epidemiology Summary

• According to DelveInsight’s estimates, in 2025, there were nearly ~226,000 diagnosed prevalent cases of ANCA Vasculitis in the 7MM.
• ANCA Vasculitis predominantly affects older adults, with peak onset typically occurring between the sixth and eighth decades of life, though cases can occur at any age. Many cohorts show a slight male predominance, but sex differences are modest and vary by region and subtype.
• As per Bataille et al. (2022), in people over 20 years of age, age-standardized prevalence rates for granulomatosis with polyangiitis (GPA) were 10 per 100,000 person-years, respectively.
• As per Hellmich et al. (2021), the prevalence of GPA is 210 cases per million people. Hence, 17,500 ANCA Vasculitis patients (GPA and MPA) are estimated to live in Germany, with an annual increase of 3,200 patients.
• As per Hwee et al. (2022), the prevalence of EGPA increased from 22.7 to 45.6 per 1,000,000 persons from 2005 to 2019 in the UK.
• As per Moura et al. (2022), particularly in GPA, ANCA Vasculitis affects 87%, 78%, 61.5%, 42.5%, 30%, 17.5%, 10%, and 3.5% in the upper respiratory tract, lower respiratory tract, renal impairment, eye involvement, cutaneous manifestation, nervous system, cardiovascular, and gastrointestinal, respectively.
• Additionally, the prevalence of these conditions is geographically heterogeneous; GPA is more prevalent in European countries, while in Asian countries (especially Japan), microscopic polyangiitis (MPA) is more prevalent.

ANCA Vasculitis Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of ANCA Vasculitis: ~226,000
• 2036 Projected Diagnosed Prevalent Cases of ANCA Vasculitis: XXXX
• ANCA Vasculitis Growth Rate (2026–2036): ~3% CAGR

DelveInsight's ‘ANCA Vasculitis Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the ANCA Vasculitis, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

ANCA Vasculitis Understanding and Diagnosis Algorithm

ANCA Vasculitis Overview

ANCA vasculitis is a rare, life-threatening autoimmune disease characterized by inflammation and destruction of small blood vessels, which can lead to significant organ damage. The disease primarily affects the kidneys, lungs, upper respiratory tract, skin, nerves, and other organs. ANCA vasculitis is broadly classified into three major subtypes: GPA, MPA, and eosinophilic granulomatosis with polyangiitis (EGPA), each differing in clinical presentation and organ involvement. The disease occurs when the immune system mistakenly attacks healthy blood vessels, leading to inflammation, reduced blood flow, and tissue damage. If left untreated, ANCA vasculitis can result in severe complications such as kidney failure, pulmonary hemorrhage, and permanent organ dysfunction.

ANCA Vasculitis Diagnosis

The diagnosis of ANCA vasculitis involves a combination of clinical evaluation, laboratory testing, imaging studies, and tissue biopsy to confirm disease subtype and assess organ involvement. Blood tests are commonly used to detect anti-neutrophil cytoplasmic antibodies (ANCA), including proteinase-3 (PR3-ANCA) and myeloperoxidase (MPO-ANCA), which are key diagnostic markers. Additional laboratory tests may include inflammatory markers, kidney function tests, and urinalysis to evaluate disease severity. Imaging techniques such as CT scans, chest X-rays, and MRI may help identify lung or sinus involvement. In many cases, a tissue biopsy of the kidney, lung, skin, or other affected organs remains the gold standard for confirming vasculitis and determining the extent of vascular inflammation. Early diagnosis is critical to initiating timely treatment and preventing irreversible organ damage.

Further details are provided in the report...

ANCA Vasculitis Epidemiology

Key Findings from ANCA Vasculitis Epidemiological Analysis and Forecast

• According to DelveInsight’s estimates, there were approximately 226,000 diagnosed prevalent cases of ANCA vasculitis across the 7MM in 2025, with the United States accounting for the highest share.
• Among EU4, Germany accounted for the largest number of diagnosed prevalent cases of ANCA Vasculitis, followed by Italy, whereas Spain accounted for the lowest cases in 2025.
• In 2025, pANCAs/MPO-ANCAs represented the most commonly diagnosed antibody-specific subtype of AAV in MPA, accounting for approximately 28,000 cases in the US.
• In 2025, the diagnosed prevalent cases of MPA by organ involvement in the UK were highest in renal impairment, followed by other organs such as the lower respiratory tract, cutaneous manifestations, gastrointestinal involvement, nervous system, upper respiratory tract, cardiovascular involvement, and eye involvement.
• Granulomatosis with polyangiitis was found to be more prevalent than any other type of ANCA Vasculitis in the United States (~35,000).

Explore DelveInsight’s ANCA Vasculitis market forecast report featuring epidemiology, emerging therapies, competitive intelligence, and forecast insights through 2036 within the 7MM countries.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of ANCA Vasculitis, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• ANCA Vasculitis Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of ANCA Vasculitis? What will be the growth opportunities across the 7MM concerning the patient population with ANCA Vasculitis?
• What is the historical and forecasted ANCA Vasculitis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.